Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04742972
Status:
WITHDRAWN
Last Update Posted:
2022-12-09
First Post:
2021-02-03
Brief Title:
Prostate PMSABR Study
Sponsor:
Darren Poon
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
PSMA-PET Guided Stereotactic Ablative Body Radiotherapy for Oligometastasis in Metastatic Castration-resistant Prostate Cancer mCRPC With Progression on Enzalutamide PMSABR Study
Status:
WITHDRAWN
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The lack of well-defined oligometastasis high disease burden in mCRPC and high sensitivity of PSMA-PET scan PMSABR study was made with high ambition and the assumption on recruitment was found to be invalid
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study the investigator aim to evaluate the role of PMSA-PET guided SABR on progression free survival PFS in patients with oligoprogressive mCRPC with Enzalutamide The potential improvement in PFS with SABR while continuing the initial-responding Enzalutamide is potentially benefiting to patients in terms of overall disease control
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None